Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cells Targeting B Cell Related Autoimmune Diseases
NCT06661811Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of Beijing Boren Hospital autologous CAR-T therapy in autoimmune disease, sponsored by Beijing Boren Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Frequency of Adverse Events and Serious Adverse Events at 24 months. Planned start Nov 2024; status: withdrawn.
02
Drugs
Beijing Boren Hospital autologous CAR-T therapy
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT06661811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06661811.